Author

Amos Hedt

Observed institution: Clarity Pharmaceuticals Ltd. (Australia)

OpenAlex ID: A5003398607

64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy

2018 · Rodney J. Hicks, Price Jackson, et al. · Journal of Nuclear Medicine · 149

Harnessing 64 Cu/ 67 Cu for a theranostic approach to pretargeted radioimmunotherapy

2020 · Outi Keinänen, Kimberly Fung, et al. · Proceedings of the National Academy of Sciences · 131

High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting

2015 · Christopher Ullman, Pascale Mathonet, et al. · PLoS ONE · 17

A Novel Theranostic Trial Design Using 64Cu/67Cu with Fully 3D Pre-Treatment Dosimetry

2019 · Dale L. Bailey, Geoffrey Schembri, et al. · Journal of Nuclear Medicine · 10

Development of 67Cu quantitative SPECT for clinical dosimetry

2018 · Kathy Willowson, Matt Harris, et al. · 2

Implementation of a whole body SPECT-CT imaging protocol for post-treatment dosimetry of 67Cu-SARTATE

2019 · Kathy Willowson, Dale L. Bailey, et al. · Journal of Nuclear Medicine · 1

First-Time-in-Human Trial of Cu-64 MeCOSAR-octreotate (CuSARTATE) for Imaging and Dosimetry Estimation in Neuroendocrine Tumor (NET)

2016 · Rodney J. Hicks, Price Jackson, et al. · Journal of Nuclear Medicine · 1

[212Pb]PSC-PEG2-TOC Therapy for NET Leads to Complete Responses in Mice Bearing SSTR2 Positive Tumors - Comparison to [177Lu]DOTATATE in a Preclinical Model

2023 · Michael K. Schultz, Dijie Liu, et al. · Endocrine Abstracts

Optimised production of 64Cu-SARTATE for a phase 1 clinical trial

2016 · Peter Roselt, Wayne Noonan, et al. · Endocrine Abstracts

Works count: 10

Citation count: 311

H-index: 4

I10-index: 4